What's Happening?
New research from the Cleveland Clinic, published in eClinicalMedicine, indicates that patients who discontinue injectable GLP-1 drugs like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) achieve the most significant two-year weight loss
if they subsequently undergo bariatric surgery. The study analyzed electronic health records of 20,486 Cleveland Clinic patients who used semaglutide or tirzepatide for at least three months between 2021 and 2023. Researchers compared five treatment strategies: continuing the initial GLP-1 medication, switching between semaglutide and tirzepatide, transitioning to another obesity medication, undergoing bariatric surgery, or discontinuing treatment without further intervention. Bariatric surgery resulted in an average 28% body weight reduction over two years. Patients who switched between semaglutide and tirzepatide saw a 16% weight loss, while those who remained on their original medication experienced nearly 11% loss. Transitioning to other obesity medications led to an 8% reduction. Conversely, patients who stopped treatment without further weight management care had the smallest average weight loss of 4% and minimal improvements in blood sugar control and blood pressure.
Why It's Important?
This study provides crucial insights for the growing number of U.S. adults using GLP-1 medications for weight loss, which climbed to 11% in 2026 from 3% in 2024. The findings highlight the importance of continued weight management strategies after discontinuing GLP-1 drugs, addressing a significant challenge for patients who stop treatment due to factors like cost, insurance limitations, or side effects. The research demonstrates that simply stopping GLP-1 medication without a follow-up plan leads to suboptimal outcomes, emphasizing the chronic nature of obesity and the need for sustained care. For healthcare providers, the study offers evidence-based guidance for patient-clinician discussions on alternative therapies, particularly bariatric surgery, which showed the most substantial benefits not only in weight loss but also in improving A1C levels for Type 2 diabetes patients and reducing blood pressure for those with hypertension. This information can help shape clinical practice and insurance coverage policies for obesity treatment in the U.S.
What's Next?
The findings from this Cleveland Clinic study are expected to be presented by lead author Hamlet Gasoyan, Ph.D., at ObesityWeek 2026, the Obesity Society’s annual meeting. This presentation will likely spark further discussions among medical professionals, researchers, and policymakers regarding optimal long-term obesity management strategies. Patients currently on or considering GLP-1 medications will be encouraged to consult their healthcare providers to discuss personalized treatment plans, especially if they anticipate discontinuing their current medication. The research team plans to continue their work in this field to help patients choose treatments based on individualized expected benefits and risks, aligning with patient preferences. This ongoing research could lead to the development of more tailored treatment pathways and potentially influence insurance coverage for bariatric surgery and other obesity medications as follow-up care after GLP-1 drug use.
Beyond the Headlines
The study underscores a broader shift in understanding obesity as a complex, chronic disease requiring continuous management rather than a temporary condition. The high rate of GLP-1 drug usage and the common reasons for discontinuation (cost, insurance, side effects) point to systemic issues within the U.S. healthcare landscape regarding access and affordability of long-term obesity treatments. The significant benefits of bariatric surgery post-GLP-1 discontinuation could reignite debates about its role as a primary or secondary intervention for weight management, potentially increasing its utilization. Furthermore, the study's emphasis on continued care highlights the ethical responsibility of healthcare systems to provide comprehensive, accessible, and sustained support for individuals struggling with obesity, moving beyond a 'one-size-fits-all' approach to personalized medicine.










